Tislelizumab with chemotherapy for previously untreated advanced squamous or non-squamous non-small-cell lung cancer

Tislelizumab is in clinical development to treat patients with advanced non-squamous or squamous non-small cell lung cancer (NSCLC) who have not received previous treatment. NSCLC makes up the majority of lung cancers in the UK. In locally advanced NSCLC, the cancer has spread beyond the lung which was initially affected. Symptoms of lung cancer include a persistent cough, shortness of breath, coughing up blood, aches and pains in the chest or shoulder, loss of appetite, weight loss and fatigue. Most patients with NSCLC are diagnosed at the advanced stage where curative treatment with surgery is unsuitable.